ViroGates accelerates commercialization of its products to aid emergency departments in prioritizing patient care.

ViroGates publishes prospectus for its initial public offering in Copenhagen.

ViroGates intends to strengthen its capital structure to intensify the continued commercial roll-out of its products and strengthen its product development, clinical documentation and global patent coverage.